Literature DB >> 11777751

Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility.

Narushi Takamatsu1, Lynda S Welage, Yayoi Hayashi, Ryuzo Yamamoto, Jeffrey L Barnett, Vinod P Shah, Lawrence J Lesko, Chandrasekharan Ramachandran, Gordon L Amidon.   

Abstract

The role of gastrointestinal motility and pH in determining cimetidine bioavailability as well as double peaks in plasma profiles following oral administration, in the quiescent or active phase of antral motility, to humans in the fasted state was examined. Plasma cimetidine-time curves did not show the presence of double peaks in any subject following intravenous administration. The incidence of double peaks was 73% following oral administration and was independent of antral migrating motility complex phase. Further, it was found that oral administration of cimetidine in the quiescent phase resulted in significantly higher bioavailability and in other pharmacokinetic parameters compared to that obtained following administration in the active phase. Excellent linearity in plots of motility peaks vs. plasma peaks with slopes close to unity were evident for both quiescent (r(2)=0.93) and active phase (r(2)=0.97) administration. A total of 14 peaks out of 22 (10 subjects, 64%) and 20 out of 27 peaks (11 subjects, 74%), were accounted for in quiescent and active phase oral administration, respectively. The proximal occurrence of plasma peaks to antral motility peaks typical of phase III contractions strongly implies that motility patterns may be responsible for secondary maxima following oral cimetidine administration in the fasted state.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2002        PMID: 11777751     DOI: 10.1016/s0939-6411(01)00207-7

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  8 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

Review 2.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

3.  Nanostructured reverse hexagonal liquid crystals sustain plasma concentrations for a poorly water-soluble drug after oral administration.

Authors:  Tri-Hung Nguyen; Tracey Hanley; Christopher J H Porter; Ben J Boyd
Journal:  Drug Deliv Transl Res       Date:  2011-12       Impact factor: 4.617

Review 4.  A Review of Food-Drug Interactions on Oral Drug Absorption.

Authors:  Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

5.  Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.

Authors:  Ekarat Jantratid; Sompol Prakongpan; Gordon L Amidon; Jennifer B Dressman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function.

Authors:  Yukiko Metsugi; Yoshihiro Miyaji; Ken-ichi Ogawara; Kazutaka Higaki; Toshikiro Kimura
Journal:  Pharm Res       Date:  2007-10-23       Impact factor: 4.200

7.  Immunomodulatory effect of cimetidine in common carp (Cyprinus carpio L.).

Authors:  Seyyed Mehdi Hosseinifard; Asieh Ahmadpour; Bagher Mojazi Amiri; Majid Razeghi Mansour; Arezo Ebrahimpour
Journal:  Fish Physiol Biochem       Date:  2013-05-24       Impact factor: 2.794

8.  A modern view of excipient effects on bioequivalence: case study of sorbitol.

Authors:  M-L Chen; A B Straughn; N Sadrieh; M Meyer; P J Faustino; A B Ciavarella; B Meibohm; C R Yates; A S Hussain
Journal:  Pharm Res       Date:  2006-10-18       Impact factor: 4.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.